Buy Vidalista Online


Active substance: Tadalafil
U.S. Brand: Cialis / Adcirca
Indian Brand: Vidalista
Mfd by:
Strength: 20, 40, 60mg
Form release: blister with 10 tablets
Shipping time: 7 – 21 days
Best price: 0.40 USD
Order: through request form


DescriptionHow to take?Common Side EffectsLatest New'sPhoto's

Vidalista 20 mg, is an FDA-approved medication used to treat erectile dysfunction problems in men. It’s the only medication proven to treat ED issues for as long as 36 hours. Vidalista 20 mg is manufactured by Centurion Lab in India.

We Sell Generic For Cialis from India – Vidalista (Tadalafil), is 100% equivalent for original tablets, made by popluar company Centurion Remedies which manufactiring only drugs for erectylie dysfunction, cheap prices guarantee by us, we have direct supply of Vidalista to our stock, we have always available Vidalsita in stock more that 10,000 pills stock. Also we offer discounts for clients who order Vidalista, you can leave reviews about these tablets and we will make discount 10% + additional discount on shipping options for Vidalista. We guarantee safety delivery and payment processing.

Tadalafil is usually taken only once per day. Follow all directions on your prescription label. Do not take this medicine in larger or smaller amounts or for longer than recommended.

Common tadalafil side effects may include:

  • headache;
  • flushing (warmth, redness, or tingly feeling);
  • nausea, upset stomach;
  • stuffy nose; or
  • muscle pain, back pain, pain in your arms or legs.

New Erectile Dysfunction Treatment Likely to Face Stiff Competition If Approved

The treatment of erectile dysfunction (ED) has helped literally tens of millions of men in America alone. The number of drugs treating ED has grown substantially over the years, and each drug tends to have a different target market within the community of those suffering from ED.

Now that Viagra and Cialis are facing generic competition, the total pool of dollars spent on treating ED after the Big Pharma patent cliffs expired is expected to drop ahead. Still, there are many newer and upcoming drugs that targeting subsets of patients with new issues around ED.

A relatively new and unheard of company called Aquestive Therapeutics Inc. (NASDAQ: AQST) has a decision on the U.S. approval of AQST-119 (tadalafil oral film) for ED coming up shortly. This company just came public in the summer of 2018. Wedbush Securities, which rates Aquestive with an Outperform rating and $34 target (versus a $17.91 prior close) sees it receiving FDA approval on or before the PDUFA date of November 18, 2018.

The question now is just how much a new ED treatment is needed for the market, as well as how much a new entrant can really make off of a new ED treatment now that Viagra is over 20 years old and with generics and lower-priced competition on the market. Wedbush posted a 90:10 probability of approval on Aquestive’s ED treatment, and it listed the following data sets in its report:

  • 1,800,000 estimated eligible patients
  • Price per patient of $3,726
  • Gross peak sales of $62.9 million
  • Peak sales year of 2024

These numbers may be great for a company with a mere $450 million market cap like Aquestive. Unfortunately, it’s a small subset of the ED market as a whole, and the total global pie treating ED is still worth hundreds of millions to billions of dollars as a whole.

The demand for drugs to treat ED has risen to meet the needs of an aging population and to help combat disease-related ED from issues around kidney disease, hypertension-related issues, chronic disorders, hormonal issues, diabetes complications and neurological disorders. Again, the dollar amounts being generated around ED is dropping due to stiff competition from generics.

Some other broader news has been around in the larger ED treatments in 2018 and in 2017 shown below.

In September of 2018, Teva Pharmaceutical Industries Ltd. (NYSE: TEVA) announced the exclusive first-to-file launch of a generic version of Cialis tablets in the United States. Eli Lilly and Co. (NYSE: LLY) tadalafil tablets are a phosphodiesterase 5 (PDE5) inhibitor for the treatment of erectile dysfunction. The Teva release showed that Cialis had annual sales of more than $1.9 billion in the United States as of July 2018. That said, due to generics and competition, Cialis sales may drip under $1 billion in 2019 or shortly thereafter.

Pfizer Inc. (NYSE: PFE) enjoyed billions of dollars in sales of its Viagra for ED, but Viagra went generic in late 2017. Pfizer makes its own generic version, as do companies like Teva, Aurobindo and Cambia.

Bayer also had Levitra, but this was a distant number-three drug behind leader Viagra and then behind Cialis.

A site called Sharecare suggests that more than 30 million men in America have a form of ED. Now think about how many more millions of men have had it who have died, and how many millions of men will have it in the future but do not yet. Does the market need yet another treatment for ED? Maybe the answer really depends on whom you ask.

Vidalista: What is it and who can use it?

Here are some key points about Cialis. More detail is in the main article.

  • Under the name Cialis, tadalafil is used to treat erectile dysfunction.
  • As Adcirca, the same drug treats pulmonary arterial hypertension and benign prostatic hyperplasia.
  • Cialis increases blood flow to the penis, enabling an erection to occur when a man is sexually stimulated.
  • Anyone with a heart condition should seek medical advice before using Cialis.
  • Cialis is a medication, with potentially serious adverse effects. It should only be obtained from a reputable source and used under medical supervision.
Cialis is the brand name for tadalafil, a drug used to treat erectile dysfunction. It is similar to Viagra and Levitra. Under the brand name Adcirca, tadalafil is used for pulmonary arterial hypertension.

Cialis increases blood flow to the penis, and this enables a man to achieve an erection. It does not lead to sexual arousal. It should be used with caution, and only under medical supervision.

Tadalafil was approved by the United States (U.S.) Food and Drug Administration (FDA) in 2003 for the treatment of erectile dysfunction (ED). It is also used to treat pulmonary arterial hypertension and benign prostatic hyperplasia, a condition in which the prostate gland becomes enlarged, causing problems with urination.

Daily Tadalafil May Be Effective for Peyronie’s Disease

Daily tadalafil has the potential to be a treatment option for Peyronie’s disease (PD), according to data presented at the Sexual Medicine Society of North America 18th Annual Fall Scientific Meeting in San Antonio, Texas.

In a small study of PD patients, treatment with the drug, a phosphodiesterase type 5 (PDE5) inhibitor that is FDA approved for treating erectile dysfunction, was associated with decreased pain on erection and degree of penile curvature and improved erectile function.

PAE Is a Promising BPH Treatment Alternative
In a study, men with Peyronie’s disease who tadalafil 5 mg per day had decreased pain on erection and degree of penile curvature.

Daily tadalafil has the potential to be a treatment option for Peyronie’s disease (PD), according to data presented at the Sexual Medicine Society of North America 18th Annual Fall Scientific Meeting in San Antonio, Texas.

In a small study of PD patients, treatment with the drug, a phosphodiesterase type 5 (PDE5) inhibitor that is FDA approved for treating erectile dysfunction, was associated with decreased pain on erection and degree of penile curvature and improved erectile function.

Pain resolution was achieved in 55%, 70%, and 78.3% of groups 1, 2, and 3, respectively, after 12 weeks, the researchers reported in a poster presentation. The changes in the mean degree of penile curvature were -4.6, -6.2, and -7.2 degrees, respectively. The changes in mean plaque size were 0.2, 0.2, and 0.3 cm2. Further, groups 2 and 3 showed a greater increase in International Index of Erectile Function (IIEF)-Erectile Function domain score compared with group 1 (3.8 and 3.8 vs 0.4, respectively). Commonly reported adverse events (AEs) included hematoma at the injection site (4 cases), myalgia (3 cases), and dyspepsia, headache, and flushing (1 case each). No patient discontinued treatment due to AEs, the investigators reported.

The new study is not the first investigation to demonstrate the potential usefulness of tadalafil in treating PD. In a paper published in Urology Annals (2015;7:345-349) Lucio Dell’Atti, MD, of University Hospital S. Anna, Ferrara, Italy, reported that combined treatment with tadalafil and IVI was associated with better pain control and reduced penile curvature and improved erectile function than IVI or tadalafil alone. The study included 59 PD patients, who were divided into 3 groups. Group A had 23 patients treated with IVI, group B had 19 patients treated with tadalafil 5 mg once daily for 12 weeks, and group C had 17 patients treated with IVI and tadalafil 5 mg once daily for 12 weeks. At baseline, groups A, B, and C had mean IIEF-5 scores of 12.90, 12.51, and 11.58, respectively.

At 12 weeks, pain resolved completely in 57%, 61%, and 76% of groups A, B, and C, respectively. The final mean curvature degree decreased in all groups, with not significant difference among the groups. Mean plaque size did not decrease significantly in group A (1.57 vs 1.59 cm2 at baseline) and group B (1.51 vs 1.52 cm2 at baseline), but decreased significantly in group C (1.46 vs 1.58 cm2 at baseline). The mean IIEF-5 score improved significantly in group C compared with groups A and B (23.1 vs 14.4 and 18.2, respectively).

Reference

Park HJ, Park NC. Daily tadalafil therapy: A new treatment option for Peyronie’s disease? Presented in poster format at the Sexual Medical Society of North American 18th Annual Fall Scientific Meeting in San Antonio, Texas. Poster 134.

Submit your review
1
2
3
4
5
Submit
     
Cancel

Create your own review

Vidalista
Average rating:  
 1 reviews
by Jan Vajda Hungary on Vidalista

It is working good.